MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Clinical trials for MULTIPLE SCLEROSIS, RELAPSING-REMITTING explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE SCLEROSIS, RELAPSING-REMITTING trials appear
Sign up with your email to follow new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could CAR T-Cells be the key to taming MS?
Disease control Not yet recruitingThis early-stage study tests a new treatment called CABA-201 for people with multiple sclerosis (MS). It uses a patient's own immune cells, modified to target and destroy certain immune cells that may be attacking the nervous system. The main goal is to check safety and find the …
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Exercise may ease sexual dysfunction in MS women
Symptom relief Not yet recruitingThis study looks at whether an online physical activity program can improve sexual dysfunction in women with relapsing-remitting multiple sclerosis. About 30 women who are in a committed relationship and have sexual problems will take part. They will wear a pedometer and complete…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated May 14, 2026 12:03 UTC
-
AI takes on MS: new study aims to personalize treatment
Knowledge-focused Not yet recruitingThis study will collect health data from 100 people with multiple sclerosis (MS) to find patterns that predict how the disease will progress. Researchers will use artificial intelligence to analyze this information, with the goal of helping doctors choose the best treatment for e…
Matched conditions: MULTIPLE SCLEROSIS, RELAPSING-REMITTING
Sponsor: Luxembourg Institute of Health • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:17 UTC